NovoCure (NVCR) vs DENTSPLY SIRONA (XRAY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
NovoCure (NVCR) has outperformed DENTSPLY SIRONA (XRAY) over the past year, losing 0.9% versus a loss of 29.8%. Over five years, XRAY leads with a -85.0% price change compared with -87.3% for NVCR. DENTSPLY SIRONA is the larger company by market cap ($1.73 billion vs $1.66 billion), about 1.0 times the size.
DENTSPLY SIRONA pays a dividend yielding 3.68%, while NovoCure does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NVCR | XRAY |
|---|---|---|
| Share price | $14.22 | $8.69 |
| Market cap | $1.66B | $1.73B |
| 1-day change | -3.00% | +1.76% |
| YTD return | +9.98% | -23.97% |
| 1-year return | -0.91% | -29.81% |
| 5-year return | -87.33% | -84.98% |
| Forward P/E | — | 5.80 |
| EPS (TTM) | $-1.30 | $-2.73 |
| Dividend yield | 0.00% | 3.68% |
| Annual dividend | $0.00 | $0.32 |
| 52-week high | $21.45 | $14.76 |
| 52-week low | $9.82 | $8.38 |
| Distance from 52-week high | -33.71% | -41.12% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +88.89% | +54.20% |
| Average volume | 1.42M | 4.76M |
| Shares outstanding | 116.45M | 199.35M |
| Employees | 1,605 | 14,000 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVCR has outperformed XRAY by 28.9 percentage points over the past year.
- DENTSPLY SIRONA offers a meaningfully higher dividend yield (3.68% vs 0.00%).
About NovoCure
NVCR stock →NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax.
Health Care · Medical/Dental Instruments · 1,605 employees
About DENTSPLY SIRONA
XRAY stock →DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide.
Health Care · Medical/Dental Instruments · 14,000 employees
NVCR vs XRAY FAQ
Which is bigger, NovoCure or DENTSPLY SIRONA?
DENTSPLY SIRONA (XRAY) is larger, with a market capitalization of $1.73B compared with $1.66B for NovoCure (NVCR).
Which stock has performed better over the past year, NVCR or XRAY?
NVCR returned -0.91% over the past 12 months, compared with -29.81% for XRAY (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, NovoCure or DENTSPLY SIRONA?
DENTSPLY SIRONA pays a dividend yielding 3.68%, while NovoCure does not currently pay a regular dividend.
Are NovoCure and DENTSPLY SIRONA in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.